Brege Laura 4
4 · Mirum Pharmaceuticals, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Mirum (MIRM) Director Laura Brege Receives Stock Awards
What Happened
Laura Brege, a director of Mirum Pharmaceuticals (MIRM), was granted two equity awards on 2026-06-15: 3,772 shares and 1,980 deferred stock units. Both grants are recorded at $0.00 (no cash paid) and are derivative awards/stock units rather than open-market purchases or sales. Total granted = 5,752 units; no immediate cash value was exchanged.
Key Details
- Transaction date: 2026-06-15 (Form filed 2026-06-17). Transaction code: A (award/grant).
- Grant prices: $0.00 for both awards; aggregate cash value at grant = $0.
- Shares owned after transaction: Not specified in this Form 4 filing.
- Footnote summary:
- F1: The 3,772-share award vests on the first anniversary of the grant, but will be fully vested no later than the issuer’s 2027 annual stockholder meeting.
- F2: The 1,980 deferred stock units each represent a contingent right to one share, vest on the first anniversary (or fully vest by the 2027 annual meeting), and will be paid in common stock upon the earlier of (i) a change in control or (ii) within 60 days after separation from service.
- Filing timeliness: Filed two days after the reported transaction date; no late filing flag in the record.
Context
These are non-cash director compensation awards and should be read as deferred/contingent equity rather than an outright buy or sale. Deferred stock units do not immediately increase tradable share count — they convert to shares only upon vesting and specified payout events (change in control or separation).
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-15+3,772→ 3,772 totalExercise: $101.00Exp: 2036-06-14→ Common Stock (3,772 underlying) - Award
Deferred Stock Units
[F2]2026-06-15+1,980→ 1,980 total→ Common Stock (1,980 underlying)
Footnotes (2)
- [F1]The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
- [F2]Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.